⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536157 | 0.87 | — | — | |
| SCHEMBL17992603 | 0.87 | — | — | |
| SCHEMBL1536155 | 0.87 | — | — | |
| SCHEMBL471704 | 0.83 | — | — | |
| SCHEMBL471705 | 0.83 | — | — | |
| SCHEMBL468282 | 0.83 | — | — | |
| SCHEMBL21310709 | 0.83 | THRB (0.32) | — | |
| SCHEMBL21466017 | 0.83 | THRB (0.32) | — | |
| Hydrochloric Acid SCHEMBL9978591 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL9980432 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515957-A | Stereoselective synthesis of intermediates for the preparation of heterocyclic compounds | 太景生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
| EP-1809280-B1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| EP-0100898-B1 | CYCLOALKYL DERIVATIVES OF BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1987-05-13 | — | — | EP | disclosed |
| US-4454068-A | Cycloalkyl derivatives of benzisoselenazolones | A. NATTERMANN & CIE GMBH (DE) | 1984-06-12 | — | — | US | disclosed |